Q1 2024 EPS Estimates for Syros Pharmaceuticals, Inc. Decreased by HC Wainwright (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) - Equities researchers at HC Wainwright cut their Q1 2024 earnings estimates for shares of Syros Pharmaceuticals in a research note issued to investors on Monday, April 1st. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($1.20) for the quarter, down from their prior estimate of ($0.91). HC Wainwright currently has a "Buy" rating and a $15.00 target price on the stock. The consensus estimate for Syros Pharmaceuticals' current full-year earnings is ($3.77) per share. HC Wainwright also issued estimates for Syros Pharmaceuticals' Q2 2024 earnings at ($1.21) EPS, Q3 2024 earnings at ($1.17) EPS, Q4 2024 earnings at ($1.18) EPS, FY2024 earnings at ($4.77) EPS, FY2025 earnings at ($4.94) EPS, FY2026 earnings at ($4.06) EPS and FY2027 earnings at ($2.93) EPS.

SYRS has been the subject of several other reports. Piper Sandler restated an "overweight" rating and set a $13.00 price objective on shares of Syros Pharmaceuticals in a research note on Wednesday. StockNews.com raised shares of Syros Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, March 28th.

Syros Pharmaceuticals Stock Performance

SYRS stock traded up $0.35 during trading on Wednesday, reaching $4.98. The company had a trading volume of 430,399 shares, compared to its average volume of 208,178. The firm has a 50-day simple moving average of $6.73 and a 200-day simple moving average of $5.10. The company has a market cap of $131.72 million, a price-to-earnings ratio of -0.86 and a beta of 1.74. The company has a debt-to-equity ratio of 2.07, a quick ratio of 3.95 and a current ratio of 3.95. Syros Pharmaceuticals has a twelve month low of $2.09 and a twelve month high of $8.17.

Institutional Trading of Syros Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in SYRS. Two Sigma Investments LP raised its holdings in Syros Pharmaceuticals by 30.0% during the first quarter. Two Sigma Investments LP now owns 13,600 shares of the company's stock worth $36,000 after purchasing an additional 3,139 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Syros Pharmaceuticals by 8.0% during the 4th quarter. Renaissance Technologies LLC now owns 47,235 shares of the company's stock worth $170,000 after buying an additional 3,500 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Syros Pharmaceuticals by 85.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,550 shares of the company's stock worth $61,000 after buying an additional 10,400 shares during the last quarter. LPL Financial LLC raised its stake in Syros Pharmaceuticals by 13.1% in the 2nd quarter. LPL Financial LLC now owns 94,075 shares of the company's stock valued at $296,000 after purchasing an additional 10,886 shares during the last quarter. Finally, Shay Capital LLC increased its stake in shares of Syros Pharmaceuticals by 87.3% during the 2nd quarter. Shay Capital LLC now owns 26,426 shares of the company's stock valued at $83,000 after acquiring an additional 12,317 shares during the last quarter. Institutional investors and hedge funds own 91.47% of the company's stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.